The investigator's research focus throughout fellowship included several retrospective studies in eosinophilic esophagitis. One of the investiagotor's studies evaluated the management of both initial and maintenance therapy for EE within our department. The investigator wanted to know what medicines the majority of pediatric gastroenterologists at the investigator's institution were using to treat EE and how often patients were being reevaluated by endoscopy. The investigator also wanted to evaluate the use of montelukast in the treatment of EE. The investigator reviewed 1500 charts of patients who had undergone upper endoscopy and had a result of "esophagitis." Patients were then selected by the presence of greater than or equal to 20 eosinophils per high power field in at least one biopsy location. Of the 1500 charts the investigator evaluated, only 88 patients fulfilled criteria for EE. The investigator discovered that there is not a consistent standard of care within their department for the initial and maintenance treatment of EE. Many different medicines are trialed initially and patients undergo esophageal biopsies at different time intervals, contrary to what is recommended. The primary group of 88 patients was then separated into 49 patients who reached maintenance therapy (defined by less than 5 eosinophils per high power field) and 39 patients who never experienced improvement in their eosinophil counts. Of the 49 who reached maintenance therapy, 30 patients were treated with montelukast and had follow up endoscopy. The investigator evaluated peak eosinophil counts pre and post treatment, and contrary to their hypothesis, those patients treated with 5mg of montelukast had lower post treatment eosinophil counts than those treated with higher doses (10 and 20mg). This raised the possibility that the packaging differences of the two main doses had an impact in treatment. The investigator considered the possibility that the lower dosage of montelukast is protective since 5mg tablets are chewable and would yield a topical effect on the esophagus whereas the 10mg tablets are swallowed, not chewed. In addition, the investigator evaluated how often EE recurred and discovered there was a high rate of histologic recurrence. Also interesting to the investigator was the lower recurrence rate in patients given 5mg of montelukast compared to 10mg and 20mg doses. These results were not expected and deserve further evaluation. If montelukast can prevent fibrosis through a topical effect, then its therapeutic potential is huge in the treatment of EE.